Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN®) Implant in Patients with Refractory Diabetic Macular Edema.

IF 2 4区 医学 Q2 OPHTHALMOLOGY
Ophthalmic Research Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI:10.1159/000540459
Warda Darwisch, Maria Della Volpe-Waizel, Philipp K Roberts, Karl T Boden, Peter Szurman, Annekatrin Rickmann
{"title":"Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN®) Implant in Patients with Refractory Diabetic Macular Edema.","authors":"Warda Darwisch, Maria Della Volpe-Waizel, Philipp K Roberts, Karl T Boden, Peter Szurman, Annekatrin Rickmann","doi":"10.1159/000540459","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME).</p><p><strong>Methods: </strong>Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments.</p><p><strong>Results: </strong>The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3).</p><p><strong>Conclusion: </strong>Even though patients' visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.</p>","PeriodicalId":19662,"journal":{"name":"Ophthalmic Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540459","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME).

Methods: Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments.

Results: The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3).

Conclusion: Even though patients' visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.

难治性糖尿病黄斑水肿患者单次植入 0.19 毫克氟西诺龙醋酸内酯 (ILUVIEN®) 后的实际效果。
简介:关于难治性糖尿病黄斑水肿(DME)患者玻璃体内氟西诺龙醋酸苷(FAc)功能和解剖结果的真实数据:关于难治性糖尿病黄斑水肿(DME)患者接受玻璃体内氟西诺龙-丙酮(FAc)治疗后的功能和解剖效果的真实数据:方法:回顾性研究44例接受过玻璃体内FAc植入治疗的慢性DME患者,这些患者曾接受过玻璃体内地塞米松、曲安奈德或抗血管内皮生长因子治疗。我们通过光谱域光学相干断层扫描(Spectralis OCT; Heidelberg Engineering)评估了最佳矫正视力(BCVA)、中央最大厚度(CMT)和眼窝厚度(FT)。次要结果包括眼内压(IOP)、不良事件、接受其他治疗的时间:结果:植入 FAc 后,CMT(基线值为 541.23 ± 155.29 µm,p < .001)和 FT(基线值为 460.34 ± 139.28 µm,p < .001)在长达 36 个月的时间内明显降低。尽管术后视力随着时间的推移有所改善,但 BCVA 与基线相比并无明显变化(0.55 ± 0.38 logMAR,p = .568)。FAc 植入效果在 21.34 ± 12.74 个月后减弱。9%的眼睛(n = 4)眼压升高,但在局部治疗(n = 1)或手术治疗(n = 3)下得到了很好的控制:结论:尽管患者的视力恢复没有明显改善,但FAc植入体在减少注射次数和减少DME方面解决了慢性DME治疗的重要支柱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ophthalmic Research
Ophthalmic Research 医学-眼科学
CiteScore
3.80
自引率
4.80%
发文量
75
审稿时长
6-12 weeks
期刊介绍: ''Ophthalmic Research'' features original papers and reviews reporting on translational and clinical studies. Authors from throughout the world cover research topics on every field in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信